Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous vasculitis

R E Hiltz1, T R Cupps

  • 1Division of Rheumatology, Immunology and Allergy, Georgetown University Medical Center, Washington, DC 20007-2197.

Current Opinion in Rheumatology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolated Candida albicans Arthritis In a Non-Intravenous Drug-Abusing Patient With Acquired Immune Deficiency Syndrome.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Arthritis and rheumatism·2002
Same author

Orbital involvement in Wegener granulomatosis: MR findings in 12 patients.

Journal of computer assisted tomography·1997
Same author

Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients.

Medicine·1995
Same author

The concomitant expression of vasculitis and coagulopathy: synergy for marked tissue ischemia.

The Journal of rheumatology·1994
Same author

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates.

Annals of internal medicine·1993
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Defining and treating cutaneous vasculitis remains challenging due to inconsistent terminology and classification. Recent advancements in recombinant cytokines and growth factors show varied therapeutic potential for these vasculopathic processes.

Area of Science:

  • Dermatology
  • Immunology
  • Pathophysiology

Background:

  • Cutaneous vasculitis and vasculopathic processes present diagnostic and therapeutic challenges.
  • Historical imprecision in terminology and classification complicates understanding.
  • The presence or absence of systemic illness adds to the complexity.

Purpose of the Study:

  • To clarify the definition, diagnosis, and treatment of cutaneous vasculitis.
  • To reduce ambiguity by applying consistent diagnostic constraints and accepted terminology.
  • To review recent case reports, basic science findings, and therapeutic applications.

Main Methods:

  • Review of recent case reports and communications on cutaneous vasculitis.
  • Analysis of basic science reports on underlying pathophysiology.

Related Experiment Videos

  • Evaluation of therapeutic roles of recombinant cytokines, growth factors, and thrombolytics.

    • Main Results:

    • Recent literature includes case reports and basic science findings on cutaneous vasculitis.
    • Technological advances have yielded new therapeutic agents like recombinant cytokines.
    • The efficacy of these agents in treating cutaneous vasculitis varies, with some showing provocative and others therapeutic effects.

    Conclusions:

    • Consistent terminology and diagnostic criteria are crucial for advancing the understanding and management of cutaneous vasculitis.
    • New therapeutic agents show potential but require further investigation for optimal use.
    • Continued research into pathophysiology and clinical applications is essential.